Clinical Trial

DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors

Study acronym: DUMAS
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to test the efficacy of induction treatment of immunotherapy and chemotherapy depending on the resection status for the treatment of non small cell lung cancer patients diagnosed with pancoast tumor. The main objectives it aims to answer are: * Complete resection rate after induction treatment with chemotherapy plus nivolumab * Overall Survival and Progression Free Survival at 24 months The sample size is 40 patients.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2023-01-05; most recent amendment 2026-04-29.
Status change: Recruiting → Active, Not Recruiting 2026-04-29
Status change: Not Yet Recruiting → Recruiting 2023-05-17
Trial Details
NCT Number NCT05684276
Lead Sponsor Fundación GECP
Conditions NSCLC, Pancoast Tumor
Enrollment 22 participants
Start Date 2023-05-12
Primary Completion 2028-03-01 (estimated)
Study Completion 2028-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-05